
GMAB Stock Forecast & Price Target
GMAB Analyst Ratings
Bulls say
Genmab's strong performance is highlighted by the worldwide net sales of its leading product, DARZALEX, which reached $3.08 billion in Q4 2024, demonstrating its robust growth trajectory and solid positioning in the multiple myeloma market. The company benefits from a diverse pipeline of candidates and recent positive clinical trial results, such as those for RYBREVANT, which showcased statistically significant progression-free survival benefits, further enhancing market confidence. With a proven track record of profitability and a strong balance sheet, Genmab is well-equipped to navigate challenges in the biotech sector while capitalizing on upcoming clinical data catalysts.
Bears say
Genmab faces significant risks that could negatively impact its financial outlook, particularly surrounding slowing sales of its leading product, Darzalex, as well as potential failures to obtain vital label extensions and negative trial outcomes. Additionally, the company may struggle with market penetration for other therapeutics like Arzerra in relapsing multiple sclerosis and Epcoritamab, which could hinder revenue growth. Furthermore, broader macroeconomic factors, including currency fluctuations and potential long-term dilution risks, contribute to the uncertain financial environment for Genmab.
This aggregate rating is based on analysts' research of Genmab - ADR and is not a guaranteed prediction by Public.com or investment advice.
GMAB Analyst Forecast & Price Prediction
Start investing in GMAB
Order type
Buy in
Order amount
Est. shares
0 shares